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ABSTRACT
ObjeCtives
To compare the frequency of discrepancies in retracted 
reports of clinical trials with those in adjacent 
unretracted reports in the same journal. 
Design
Blinded case-control study.
setting
Journals in PubMed.
POPulatiOn 
50 manuscripts, classified on PubMed as retracted 
clinical trials, paired with 50 adjacent unretracted 
manuscripts from the same journals. Reports were 
randomly selected from PubMed in December 2012, 
with no restriction on publication date. Controls were 
the preceding unretracted clinical trial published in the 
same journal. All traces of retraction were removed. 
Three scientists, blinded to the retraction status of 
individual reports, reviewed all 100 trial reports for 
discrepancies. Discrepancies were pooled and cross 
checked before being counted into prespecified 
categories. Only then was the retraction status 
unblinded for analysis.
Main OutCOMe Measure
Total number of discrepancies (defined as 
mathematically or logically contradictory statements) 
in each clinical trial report.
results
Of 479 discrepancies found in the 100 trial reports, 
348 were in the 50 retracted reports and 131 in the 50 
unretracted reports. On average, individual retracted 
reports had a greater number of discrepancies than 
unretracted reports (median 4 (interquartile range 
2-8.75) v 0 (0-5); P<0.001). Papers with a discrepancy 
were significantly more likely to be retracted than 
those without a discrepancy (odds ratio 5.7 (95% 
confidence interval 2.2 to 14.5); P<0.001). In particular, 
three types of discrepancy arose significantly more 
frequently in retracted than unretracted reports: 
factual discrepancies (P=0.002), arithmetical errors 
(P=0.01), and missed P values (P=0.02). Results from a 
retrospective analysis indicated that citations and 
journal impact factor were unlikely to affect the result.
COnClusiOns
Discrepancies in published trial reports should no 
longer be assumed to be unimportant. Scientists, 
blinded to retraction status and with no specialist skill 
in the field, identify significantly more discrepancies in 
retracted than unretracted reports of clinical trials. 
Discrepancies could be an early and accessible signal 
of unreliability in clinical trial reports.
Introduction
Landmark science cannot always be replicated inde-
pendently.1-3  Erroneous research is not uncommon4 5 
and wastes intellectual and financial resources. More 
importantly, incorrect results may spawn further clini-
cal research that needlessly draws more patients into 
trials that would not have been initiated had the origi-
nal research been reported correctly. In some cases, 
insecure clinical trials can harm patients when doctors 
implement their findings in good faith.6-8
In the specialty of bone marrow stem cell therapy for 
heart disease, for example, readers are faced with a 
wide spectrum of conflicting effect sizes that conven-
tional meta-analyses have been unable to explain. In 
this field, we have recently reported that the number of 
mathematical or logical discrepancies per trial are the 
strongest determinant of the effect size reported by the 
trial.9  However, currently, such discrepancies are 
assumed by some journals to be unimportant and not 
worth highlighting to readers.10  Reaction to the identi-
fication of hundreds of discrepancies in only one field 
varied from interest11  to criticism that the entire analy-
sis should be “set aside” and that discrepancies should 
be routinely accepted as insignificant “flubs”.12
Although the number of retractions are increasing,13 
it remains far lower than the rate of erroneous research,5 
implying that the literature may be burdened by a sub-
stantial proportion of findings that are insecure but 
unretracted and therefore unrecognised. If discrepan-
cies are more common in retracted studies than unre-
tracted studies, they might represent an accessible 
signal of concern for readers. We therefore investigated 
whether discrepancies are more prevalent in retracted 
than adjacent unretracted reports in the same journals.
Methods
We undertook a blinded case-control study. We identi-
fied discrepancies in randomly selected retracted 
 clinical trial reports, using, in each case, the preceding 
unretracted trial report in the same journal as the  control. 
WhAT IS AlReAdy knoWn on ThIS TopIC
Discrepancies (defined as mathematically or logically contradictory statements) 
can occur in published papers
Whether they matter is disputed, with some experts advising that they be set aside
Some journals will not share discrepancies reported after a fixed time limit or which 
require more than a certain word limit to communicate
WhAT ThIS STudy AddS
Scientists—blinded to retraction status and with no specialist skill the field—
identified significantly more discrepancies in retracted than unretracted clinical 
trial reports
Discrepancies in published clinical trial reports should no longer be assumed to be 
unimportant and may be an early and accessible signal of unreliability 
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We used the same journal because this factor has been 
identified as a major source of variation in retraction 
rates.14 Annotations of retraction were removed, and the 
studies were presented in random order to three scien-
tists, who were asked to remain blinded to retraction 
status.
A PubMed search was conducted in December 2012 
for the “retracted publication” publication type and 
limited to clinical trials, with no restriction on publica-
tion date. We used a computer random number genera-
tor (Microsoft Excel RAND function) to select members 
of this set until 50 numbers had been selected. For each 
trial, a paired control trial was also selected (defined as 
the unretracted clinical trial) in the same journal, 
whose PubMed accession sequence was immediately 
preceding the retracted trial. Watermarks of retraction 
were removed. The resulting 100 trials were given ran-
dom sequence numbers between 1 and 100. We decided 
on a study size of 100 trial reports as a manageable 
number that could be studied by three scientists, given 
our previous experience examining reports for discrep-
ancies.9 The PDF files of each report were presented to 
three scientists (GDC, ANN, MM), who were unaware of 
individual retraction status and asked to refrain from 
finding this out. Each scientist independently identified 
factual or mathematical discrepancies without recourse 
to specialist knowledge. 
Candidate discrepancies proposed by each scientist 
were pooled and duplicate candidates removed. All 
three scientists, joined by a fourth senior scientist 
(DPF), then examined all unique candidate discrepan-
cies and gave an opinion on their individual validity as 
a discrepancy. At this stage, conferring was allowed. 
Discrepancies were only accepted as valid if agreed as 
discrepancies by all four scientists. Table 1 shows cate-
gories of discrepancy, along with examples.
statistical analysis
Descriptive statistics
The study was then unblinded and the reports 
re-paired. Overall discrepancy counts, and overall 
counts for the different categories, were compared 
between the 50 retracted and the 50 unretracted reports 
by the Wilcoxon signed-rank test. Odds ratios and their 
confidence intervals were calculated for comparisons 
between retracted and unretracted studies and the 
presence or absence of discrepancies.19
Regression analysis
The number of discrepancies between retracted and 
unretracted based could be driven by an extreme num-
ber of discrepancies in some retracted papers. Taking 
this factor into consideration in a reanalysis, we quan-
tified the association between retraction status and the 
number of discrepancies by modelling the number of 
discrepancies using a zero inflated, negative binomial 
model. We also used this model to consider the effect of 
retraction status, year of publication, citations of the 
trial report, and journal impact factor on discrepancy 
counts. Regression coefficients were presented as inci-
dence rate ratios for the binomial component and odds 
ratios for the excess zero component.
Sensitivity and specificity analysis
We calculated the sensitivity and specificity of detecting 
retraction for a range of cut-off thresholds of discrepancy 
count, and the odds ratio for retraction above these 
thresholds. Statistical analysis was undertaken by use of 
the R project for statistical computing20-25 (code shown in 
web appendix 1), with figures prepared using ggplot2.26
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in dissemination.
Results
trial reports
The search yielded 263 retracted reports of clinical trials 
published between 1983 and 2012, from which 50 were 
randomly selected. Twenty three (46%) reports were 
retracted for misconduct, nine (18%) for errors, seven 
(14%) for plagiarism and five (10%) for duplication. 
table 1 | Categories of discrepancy
name Description example nature of discrepancy
Possible 
percentages
A percentage of a group of patients that does not match the 
subset count displayed but could fit a different subset count
23 of 57 (42%) of patients in intervention group 
were taking an ACE inhibitor15
23/57 is 40%, not 42%; 42% of 57 
patients could, however, arise from 
24 patients
Impossible 
percentages
A percentage of a group of patients that cannot exist without 
fractional patients
31.2% of 200 patients had an infarct in the right 
coronary artery.16
Each patient represents 0.5% of the 
group. Percentages must therefore be 
multiples of 0.5%, and 31.2% is not
Factual 
discrepancies
Two statements that cannot both be true Abstract: Base excess was 1.04 (SD 0.3) in 
balanced group at baseline.17 Results: Base excess 
was 1.16 (SD 0.3) in balanced group at baseline17
Abstract and results are mutually 
contradictory
Impossible 
summary statistics
Summary statistics (mean, median, range, standard deviation) 
that are not possible, based on the data presented
Median ICU stay in unbalanced group is 13 days. 
ICU stay ranged from 14 to 444 days17
Median must lie within range
Arithmetical errors Arithmetical errors such as subgroups that do not add up to 
the total parent group, or differences between before and after 
measurements that do not match the documented change
Three subgroups of size five, five, and six 
patients received different doses of treatment. 
Total number treated, 15 patients18
The three subgroups add to 16 
patients, but the total is said to be 15
Missed P values Two groups which are significantly different but are implied to 
be not different (either explicitly or by omission of a symbol 
when other comparisons are marked)
Baseline ejection fraction in two groups of 29.4 
(SD 12.7; n=191) and 36.1 (SD 13.8; n=200) 
described as comparable16
The published data are sufficient to 
calculate that the two groups are 
significantly different (P<0.001)
ACE=angiotensin converting enzyme; ICU=intensive care unit; SD=standard deviation.
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In six (12%) papers, the reason for retraction was not 
stated or unclear. Web appendix 2 shows the PubMed 
identification numbers and number of discrepancies 
found in each report.
Web appendix 3 lists the trial reports and identified 
discrepancies. To allow readers to appreciate the find-
ings of our study without necessarily seeing the identi-
ties of the trials or authors, each trial report is 
referenced by a code (R1 to R100). Nevertheless, and 
only to ensure verifiability, the discrepancies can be 
viewed in the original reports by entering the PubMed 
IDs in web appendix 2 at www.pubmed.org.
Overall discrepancy counts
Of 479 discrepancies found in the 100 trial reports, 348 
were in the 50 retracted reports and 131 in the 50 unre-
tracted reports. The overall number of discrepancies 
was 2.7-fold higher for the 50 retracted reports than for 
the 50 unretracted reports. Individual report discrep-
ancy counts were higher in retracted (median 4 (inter-
quartile range 2-8.75)) than unretracted reports (median 
0 (0-5), P<0.001).
We found discrepancies in 42 (84%) of 50 retracted 
trials and 24 (48%) of 50 unretracted trials. Of the 
remaining eight retracted trials with no discrepancies, 
the reason for retraction was misconduct in four, error 
in two, and duplication in two. Papers with a discrep-
ancy were significantly more likely to be retracted than 
those without a discrepancy (odds ratio 5.7 (95% confi-
dence interval 2.2 to 14.5), P<0.001).
Regression analysis
We considered the number of discrepancies in trial 
reports to be a broadly negative binomial distribution 
but with a certain excess proportion of reports with 
zero discrepancies. We therefore used a zero inflated, 
 negative binomial regression to investigate the relations 
between the number of discrepancies and retraction 
status, year, impact factor of the journal, and number of 
citations.
Retracted papers were more likely than unretracted 
papers to have discrepancies, and more of them. In the 
formal analysis, the number of excess zeros showed a 
significant relation to retraction status. In this model, 
retracted reports were less likely than unretracted 
reports to have excess zero discrepancies (odds ratio 
0.14 (95% confidence interval 0.03 to 0.67), P=0.01). No 
significant association was seen in relation to the year 
of publication, impact factor, and number of citations 
(table 2). This same pattern was seen in a univariable 
analysis (0.11 (0.01 to 0.79), P=0.03).
Similarly, the number of discrepancies was signifi-
cantly related to retraction status. Retracted reports had 
significantly more discrepancies than unretracted 
reports (incidence rate ratio 1.79 (95% confidence inter-
val 1.07 to 2.99), P=0.03). This same pattern was seen in 
a univariable analysis (1.62 (0.97 to 2.69), P=0.06). No 
significant association was seen in relation to the year 
of publication, impact factor, and number of citations 
(table 2).
types of discrepancy
Some prespecified discrepancy types were significantly 
more likely to be found in retracted trials than unre-
tracted trials (fig 2). These types were factual discrepan-
cies (median 1 (interquartile range 0-3, range 0-18) 
v median 0 (0-0, 0-11); P=0.002), arithmetical errors (0 
(0-0, range 0-2) v 0 (0-0, 0-6); P=0.01), and missed P 
values (0 (0-0, 0-12) v 0 (0-0, 0-0); P=0.02). For types of 
discrepancy that did not show a significant difference, 
the direction of the trend was in each case towards more 
discrepancies in the retracted trial reports.
40 30 20 10 0 10 20 30 40
Number of discrepancies
Unretracted trial reports Retracted trial reports
Pairs of trial reports
Fig 1 | Discrepancy counts. Paired comparison between retracted reports (right) and unretracted control counterparts (left) for all 100 reports studied. 
each bar represents the number of discrepancies in one trial. Pairs are ordered by total number of discrepancies in the pair, with those with the most 
discrepancies at the bottom
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sensitivity and specificity
We considered whether a particular discrepancy thresh-
old could identify retracted reports by performing a sen-
sitivity-specificity analysis on all 100 trial reports (fig 3). 
A reader, unaware of retraction status and applying a 
cut-off point of three or more discrepancies, would have 
identified retracted papers with 70% sensitivity and 
66% specificity (fig 3). The usefulness of this in terms of 
positive predictive value for identification of problems 
serious enough to cause retraction will depend on prev-
alence and will therefore vary. We do not suggest that 
trial reports be discounted simply based on reaching a 
threshold number of discrepancies, but rather that the 
presence of discrepancies might act as a prompt for the 
authors to provide the community with access to the raw 
data, in order to secure trust in the result. In our sample, 
most of the unretracted reports had no discrepancies 
and 92% had fewer than 10.
independent identification of discrepancies
Our study design involved three scientists (perhaps simu-
lating reviewers of a manuscript) and one senior scientist 
(perhaps simulating a final decision maker on publica-
tion of a manuscript). For any discrepancy to be consid-
ered valid, all four had to agree that there was no viable 
explanation present in the trial report. Of 479 discrepan-
cies, 299 (62%) were identified by one of the scientists, 78 
(16%) were independently identified by two scientists, 
and 69 (14%) were independently identified by all three 
scientists. Thirty three (7%) additional discrepancies 
were noticed by the senior scientist (and subsequently 
agreed by all others). The time spent by a scientist reading 
a trial report was available for 269 (90%) of the 300 read-
ings of trial reports (three scientists each reading 100). 
The median time spent by a scientist on a trial report was 
23 minutes (interquartile range 11-38).
Consideration of potential confounders
We conducted a reanalysis of the following potential 
confounders that might mediate an association of dis-
crepancies with retraction status:
•	 Time (because the rate of retraction of literature may 
have changed over time)
•	 Citations (because more frequent citation might sig-
nify greater scrutiny)
•	 Journal impact factor (because retraction has been 
associated with a higher impact factor).
Using a zero inflated negative binomial model, we saw 
no significant association between any of these poten-
tial confounders and the number of discrepancies 
(table 2).
discussion
Principal findings and implications
This study indicates that the presence of discrepancies in 
a study report should not be assumed to be meaningless. 
150 120 90 60 30 0 30 60 90 120 150
Discrepancies in all reports
Unretracted trial reports Retracted trial reports
Impossible
percentages
Factual
discrepancies
Possible percentages
Impossible
summary statistics
Arithmetical errors
Missed P values
P=0.44
P=0.002
P=0.68
P=0.27
P=0.01
P=0.02
Fig 2 | total number of discrepancies by type across all 100 trial reports. each bar represents 
the total number of one type of discrepancy in 50 trial reports. On the left are those found 
in unretracted control reports. On the right are those found in retracted reports 
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Fig 3 | sensitivity and specificity of the total number of 
discrepancies in a trial report exceeding a threshold, and 
retraction
table 2 | Zero inflated negative binomial analysis of 
discrepancies, retraction status, year of publication, 
journal impact factor, and trial report citations.  Only 
retraction status was significantly associated in both the 
excess zero components (negatively, in that trial reports 
are less likely to have zero discrepancies) and binomial 
components (positively, in that retracted trial reports are 
more components of the model)
incidence rate ratio or 
odds ratio* (95% Ci) P
univariable analysis
Binomial component
 Intercept 4.65 (3.03 to 7.15) <0.001
 Retraction 1.62 (0.97 to 2.69) 0.06
Excess zero component
 Intercept 0.78 (0.37 to 1.62) 0.50
 Retraction 0.11 (0.01 to 0.79) 0.03
Multivariable analysis
Binomial component
 Intercept 2.45 (0.90 to 6.65) 0.08
 Retraction 1.79 (1.07 to 2.99) 0.03
 Year 1.05 (0.99 to 1.11) 0.11
 Impact factor 0.95 (0.90 to 1.00) 0.07
 Citations 1.00 (1.00 to 1.01) 0.24
Excess zero component
 Intercept 4.22 (0.41 to 43.2) 0.23
 Retraction 0.14 (0.03 to 0.67) 0.01
 Year 0.88 (0.76 to 1.02) 0.08
 Impact factor 0.98 (0.83 to 1.16) 0.79
 Citations 1.01 (1.00 to 1.01) 0.26
*Incidence rate ratios for binomial components, odds ratios for excess 
zero components.
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Discrepancies are significantly more common in 
retracted rather than unretracted articles.
Peer reviewers and other readers may benefit from 
this knowledge because it is notoriously difficult for 
them to evaluate the reliability of a trial’s findings. It is 
already known27-29 that the presence of certain features 
of study design such as blinding, formal enrolment, 
and automated documentation of results can substan-
tially affect reported effect size. Our study goes beyond 
this to suggest that identification of discrepancies, even 
by scientists without particular scientific specialism in 
the field, might provide an early alarm of unreliability. 
When doubt exists, it may be practical to repeat some 
types of scientific study. This is usually not practical for 
clinical trials, on grounds of time and expense, so there 
is additional value in readers being able to gauge the 
reliability of existing reports.
Although the presence of discrepancies seems sensi-
tive to serious problems within trial reports, it is not 
specific, in that there are many trial reports in good 
standing with discrepancies. We do not propose that 
any particular discrepancy threshold should be used as 
an absolute level for identifying unreliable trial reports. 
However, it might help to identify trial reports, in which 
additional documentation from authors might be 
important to provide reassurance that a study has been 
reported reliably.
Journals could help in additional ways. Providing a 
post publication forum for readers to share knowledge 
of discrepancies is important, because, as our study 
shows, one reader may spot only a subset of the dis-
crepancies noticed by multiple readers. We believe this 
finding highlights the difficulty of the task and the 
likely benefits of crowd sourcing when examining 
papers after publication. In our study, six retracted tri-
als and seven unretracted trials had a letter to the editor 
published or a critical editorial raising concerns. Only 
one of these letters in each group mentioned any dis-
crepancies.
A journal could plan an automatic escalation proto-
col that would minimise consumption of editorial time. 
Once it receives a list of discrepancies, it could publish 
them immediately and request an online supplement 
of individual patient data from the paper’s authors, if 
such a supplement was not already provided in the 
original publication. The journal could publish the 
time in days and hours from request to receipt. In hon-
estly conducted trials with innocent errors (for exam-
ple, honest, simple transcription errors), these would 
be identified as such and quickly corrected. Readers 
might draw their own conclusions if the dataset is 
delayed or unavailable.7  30 
We propose this approach of requesting the raw data 
for two reasons. Firstly, if the authors were asked to 
rerun the analyses or present an explanation instead, 
this could take time to conduct and even more time to 
achieve agreement between authors. By contrast, the 
raw data can simply be released by the corresponding 
author, as there should be no debate. Secondly, such a 
policy would encourage researchers with nothing to 
hide to provide the full data as an online supplement in 
the original publication without waiting for discrepan-
cies to be identified.
Without such protocols and related amendments, 
journal reviewers and editors must individually find 
and evaluate the significance of discrepancies. An alter-
native is that the many eyes of readers could be har-
nessed in crowd sourced analytical capacity, who 
would know that their observations contribute to sci-
ence. Journals could respond at an administrative level 
without consuming scarce editorial time. Authors 
would also know that publication would provide genu-
ine scrutiny, not routinely provided or even intended by 
prepublication peer review.31  An alternative mecha-
nism for readers to communicate discrepancies to other 
readers would be an annotation system such as PubMed 
Commons or Pubpeer. This circumvents the system of 
letters to the editor, which is becoming unfit for this 
purpose because of word count limits and short six 
week limitation periods in some journals.10
Who would do the work of analysing the raw data? 
Meta-analysts are likely to have time and motivation for 
this, but so would any reader who wanted to find out 
the correct answer efficiently. The currently practiced 
approach, which is to write a letter to the editor, is inef-
fective. For example, even asking about the registered 
primary endpoint of a trial,32  in which the data seemed 
to be inexplicably missing from the publication,33  may 
yield an unrevealing reply.34  Worse, if the replacement 
endpoint is different between abstract (and shareholder 
prospectus35 ) versus individual patient data,36  the 
mathematical impossibility can be stonewalled. Worst 
of all, statistical experts in the field37  can fail to notice 
this and instead highlight the queries as being “respon-
sibly rebutted.”38
study limitations
We recognise that even our list of discrepancies 
(errors) may itself contain errors. Moreover, we have 
not attempted to establish the mechanism for the dis-
crepancies. We have no way of knowing where each 
lies on the spectrum from innocent administrative 
error to intentional fabrication. The strength of our 
non-judgmental approach is that the presence of dis-
crepancies, rather than any inferred mechanism, is 
the signal that a trial may be unsound. Author provi-
sion of raw data would allow readers to judge the 
importance of the identified discrepancies and assist 
appropriate resolution.
We chose our controls to be the preceding clinical 
trial in the same journal. Our reasoning was that con-
trolling for journal editorial processes, impact factor,14 
readership, and the journal’s postpublication policy 
was the priority. Instead of using a fixed protocol to 
identify the control report, it might have been prefera-
ble to use individual judgment to select an unretracted 
report matched for subject matter. However, we consid-
ered that attempting to do this would open the study to 
bias in such selection. Although our study is not able to 
confidently state whether the observed pattern is 
changing over time, each control report was very close 
in time to its counterpart retracted report.
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The overall number of discrepancies (of any type) 
was significantly different between retracted and unre-
tracted trial reports. For every type of discrepancy, the 
individual count for that type was numerically higher in 
retracted than unretracted trial reports; for three types 
(arithmetical errors, factual discrepancies, and missed 
P values), this difference between retracted and unre-
tracted reports was statistically significant. This reanal-
ysis that separated the types of discrepancy did not 
have power to adequately test each type individually. 
Whether some types of discrepancy are particularly 
strong markers of trial report unreliability inde-
pendently therefore remains uncertain. It is also 
unknown whether some types of discrepancy imply a 
mechanism (for example, fabrication) and should be 
considered especially concerning. Alternatively, some 
readers might be particularly concerned by discrepan-
cies that have immediate therapeutic implications for 
patients (for example, miscalculations of therapeutic 
effect size or significance).
In addition, the sample size was constrained by 
resources because of the time taken to identify, verify, 
and collate the 479 discrepancies in 100 trial reports, 
and was not based on a formal power calculation. 
Future researchers could address other such trial 
reports or even reassess the trial reports we analysed.
Misclassified clinical trials—subgroup analysis of 
pairs of reports meeting a stricter definition of 
“clinical trial”
During the study, it became apparent that some of the 
publications identified during the PubMed search 
would not generally be considered clinical trials of a 
therapeutic intervention. We performed an additional 
reanalysis that adopted an aggressive strategy of 
removing all pairs of clinical trials listed in PubMed 
where one of the pair was not actually a clinical trial. 
This reselection process left 68 trial reports in 34 pairs, 
where both would be generally recognised as clinical 
trials. Web appendix 4 shows all the figures redrawn 
for this subgroup. The pattern observed in the 100 trial 
reports classified as clinical trials in PubMed remained 
evident in this subgroup of trials with a therapeutic 
intervention. 
Of 335 discrepancies in the 68 trial reports, 254 were 
in the 34 retracted reports and 81 were in the 34 unre-
tracted reports. The overall numbers of discrepancies 
were 3.1-fold higher for the retracted reports than the 
unretracted reports. Individual discrepancy counts 
remained higher in retracted reports than unretracted 
reports (median 5 (interquartile range 3-8.75) v 0.5 
(0-4.75); P<0.001). 
Thirty two (94%) of 34 retracted reports and 17 (50%) of 
34 unretracted reports contained discrepancies. Papers 
with a discrepancy were significantly more likely to be 
retracted than those without a discrepancy (odds ratio 16 
(95% confidence interval 3.3 to 78), P<0.001). Using zero 
inflated negative binomial models, results of the univari-
able and multivariable analyses in this subgroup (web 
appendix 5) showed a trend similar to the larger dataset, 
but with wider confidence intervals, owing to a reduced 
sample size. A threshold of three or more discrepancies 
showed 76% sensitivity and 68% specificity for identify-
ing retracted reports in this subgroup. 
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Web appendix 1: R code used to analyse our data
Web appendix 2: Paired comparison between 
retracted cases (right) and unretracted control 
counterparts (left). Pairs are ordered by total number 
of discrepancies in the pair, with those with most 
discrepancies at the top
Web appendix 3: List of discrepancies found in the 
100 clinical trial reports
Web appendix 4: Figures 1, 2, and 3 redrawn for the 
reanalysis of trial reports with an aggressive strategy of 
removing all pairs of PubMed-listed clinical trials 
where one of the pair was not actually a clinical trial of 
an intervention
Web appendix 5: Table 2 for the reanalysis of trial 
reports with an aggressive strategy of removing all 
pairs of PubMed-listed clinical trials where one of the 
pair was not actually a clinical trial of an intervention. 
The upper table shows the univariable analysis. The 
lower table shows the multivariable analysis
Web appendix 6: Dataset to permit re-analysis in R 
with code available in web appendix 1
